Magenta Therapeutics Announces Closing of Initial Public Offering

From Startup Magenta Therapeutics

Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-announces-closing-initial-public-offering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 25, 2018–
Magenta
Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology
company developing novel medicines to bring the curative power of bone
marrow transplant to more patients, today announced the closing of its
initial public offering of 6,666,667 shares of its common stock at a
price to the public of $15.00 per share. The gross proceeds from this
offering, before deducting underwriting discounts and commissions and
other offering expenses, are approximately $100,000,000. In addition,
the underwriters have a 30-day option to purchase up to 1,000,000
additional shares of common stock at the initial public offering price
less underwriting discounts and commissions. Magenta Therapeutics’
common stock began trading on the Nasdaq Global Market on June 21, 2018
under the symbol “MGTA.”

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book
running managers for the offering. Wedbush PacGrow is acting as lead
manager for the offering.

The offering will be made only by means of a prospectus. Copies of the
final prospectus related to the offering may be obtained from:

J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204

Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New
York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or
by emailing Prospectus-ny@ny.email.gs.com
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department,
telephone: 631-274-2806.

Important InformationA registration statement relating to
the offering has been filed with, and declared effective by, the United
States Securities and Exchange Commission (“SEC”). Copies of the
registration statement can be accessed through the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful before registration or
qualification under the securities laws of that state or jurisdiction.

About Magenta TherapeuticsHeadquartered in Cambridge,
Mass., Magenta Therapeutics is a clinical-stage biotechnology company
developing therapeutics focused on critical areas of unmet need in the
field of bone marrow transplant for patients with autoimmune diseases,
blood cancers and genetic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180625006210/en/
Source: Magenta Therapeutics, Inc.

Magenta Therapeutics:Manisha Pai, 857-242-1155Vice
President, Communications & Investor Relationsmpai@magentatx.com

Please visit their site for more information: Magenta Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-07-05 19:55:56